SYNERGENE THERAPEUTICS
SynerGene Therapeutics is a biotechnology company with focuses on developing gene-based nanotech cancer therapeutics and diagnostics. It was incorporated in 1998 and is based in Potomac, Maryland.
SYNERGENE THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
1998-01-01
Address:
Potomac, Maryland, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
10.32 M USD
Similar Organizations
Sagimet Biosciences
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Aopia Biosciences
Aopia Biosciences is a biotechnology business focused on developing cutting-edge bioengineering solutions and technologies.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Meditope Biosciences
Meditope Biosciences is a biotechnology company focused on developing antibody-based cancer therapeutics.
Mitra Medical Technology
Mitra Medical Technology is a biomedical company developing systems for systemic cancer therapy and diagnosis.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Tempest Therapeutics
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.
Current Employees Featured
Founder
More informations about "SynerGene Therapeutics"
SynerGene Therapeutics Company Profile 2024: Valuation, Funding ...
Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; US-20240366507-A1: Methods of treating neurologic disorders: Pending: 30-Mar-2023See details»
SynerGene Therapeutics - Contacts, Employees, Board Members, …
SynerGene Therapeutics is a biotechnology company with focuses on developing gene-based nanotech cancer therapeutics and diagnostics.See details»
SynerGene Therapeutics Inc - Company Profile and News
Company profile page for SynerGene Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
SynerGene Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore SynerGene Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 6 clinical trials, 2 news, and 18 literature, Drug:SGT-53, SGT-94. ... The statistics for …See details»
SYNERGENE THERAPEUTICS, INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for SYNERGENE THERAPEUTICS, INC. of Annapolis, MD. Get the latest business insights from Dun & Bradstreet.See details»
SynerGene Therapeutics - Products, Competitors, Financials, …
SynerGene Therapeutics is a biopharmaceutical company that is developing targeted diagnostics and therapeutics in the areas of cancer, vaccine delivery, and neurological disorders. …See details»
SynerGene Therapeutics - Crunchbase
SynerGene Therapeutics is a biotechnology company with focuses on developing gene-based nanotech cancer therapeutics and diagnostics. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. …See details»
TP53 Gene Therapy as a Potential Treatment for Patients with …
A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock Locked padlock icon ... J.B.H. and S.S.K. are employees of …See details»
SynerGene Therapeutics - Craft
SynerGene Therapeutics is a biopharmaceutical company that develops targeted diagnostics and therapeutics solutions. The company focuses on the areas of cancer, vaccine delivery, and …See details»
A tumor‐targeting nanomedicine carrying the p53 gene crosses …
Nov 1, 2019 The patents have been licensed to SynerGene Therapeutics, Inc. for commercial development. E.H.C. owns an equity interest in SynerGene Therapeutics, Inc. and serves as a …See details»
Safety and Efficacy in Advanced Solid Tumors of a Targeted …
Aug 2, 2016 The patents have been licensed to SynerGene Therapeutics for commercial development. E.H.C. owns equity interests in SynerGene. In addition, E.H.C. serves as a …See details»
A Novel P53 Nanomedicine Reduces Immunosuppression and
Oct 31, 2022 2 SynerGene Therapeutics, Inc., Potomac, MD 20854, USA. 3 College of Medicine and Science, Mayo Clinic, Rochester, MN 55905, USA. PMID: 36359830 DOI: …See details»
TP53 Gene Therapy as a Potential Treatment for Patients with …
Mar 31, 2022 J.B.H. and S.S.K. are employees of SynerGene Therapeutics, Inc. E.H.C. is a consultant of SynerGene Therapeutics, Inc., and is an inventor on patents related to SGT-53 …See details»
Drugging p53 in cancer: one protein, many targets - Nature
Oct 10, 2022 For example, SGT-53, a cationic liposome developed by SynerGene Therapeutics, carrying wtp53-encoding DNA that homes selectively to tumour cells via an anti-transferrin …See details»
Nanomedicine-Based Gene Delivery for a Truncated Tumor …
Oct 18, 2022 The patents have been licensed to SynerGene Therapeutics, Inc. for commercial development. E.H.C. owns an equity interest in SynerGene Therapeutics, Inc. and serves as a …See details»
A Phase l Study of a Tumor-targeted Systemic Nanodelivery
6 SynerGene Therapeutics, Inc., Potomac, Maryland, USA. PMID: 27480598 PMCID: PMC5023382 DOI: 10.1038/mt.2016.118 Abstract Gene therapy development has been …See details»
A tumor‐targeting nanomedicine carrying the p53 gene crosses …
Jun 26, 2019 Conflict of interest: E.H.C. is the one of inventors of the described technology, for which several patents owned by Georgetown University have been issued. The patents have …See details»
Combination with SGT-53 overcomes tumor resistance to a …
Aug 1, 2018 The patents have been licensed to SynerGene Therapeutics for commercial development. Dr. Chang owns an equity interest in SynerGene Therapeutics and serves as a …See details»
Nanomedicine-Based Gene Delivery for a Truncated Tumor
Oct 18, 2022 2 SynerGene Therapeutics, Inc., Potomac, MD 20854, USA. 3 College of Medicine and Science, Mayo Clinic, Rochester, MN 55905, USA. PMID: 36291878 DOI: …See details»
Combination with SGT-53 overcomes tumor resistance to a
Aug 1, 2018 2 SynerGene Therapeutics, Inc., Potomac, MD, USA. PMID: 30288347 PMCID: PMC6169574 DOI: 10.1080/2162402X.2018.1484982 Abstract The tumor suppressor p53 …See details»